Get started

Glandpharma

ERIS Lifesciences for 25% gainsDate: 3 Dec’24 Symbol: ERIS Timeframe: Weekly ERIS Lifesciences currently seems to be in Wave V of 3 which is heading towards 1960-70 (25% from current price of 1470) as seen in the chart. Wave 4 could then correct back to 1300 levels. The company, in the recently announced September quarter results has posted best ever revenues and operating profits. This is not a prediction but a possible wave count. This is also not a recommendation to trade or invest. Please do your own analysis. HINGLISH VERSION ERIS Lifesciences vartamaan mein Wave 3 ki V mein dikh rahee hai jo 1960-70 (vartamaan keemat 1470 se 25%) kee taraf badh rahee hai jaisa ki chart mein dekh sakte hain. Wave 4 phir 1300 ke star tak neeche aa sakta hai. Company ne haal hee mein ghoshit September quarter results mein ab tak ka sabse achchha revenue aur operating profit darj kiya hai. Yah koi prediction nahin balki sambhaavit Wave count hai. Yah trade lene ya invest karne ki bhi salaah nahi hai. Kripya apana vishleshan khud karein.
NSE:ERISLong
by DhandhaPaani
GLAND Analysis & PredictionThis is the analysis of GLAND in Daily Time Frame. Watch carefully. The chart explains itself. The stock managed to break the long term resistance with increasing volume. It can retest the breakout level. If it will sustain above the breakout level, it is good for the stock. Generally Multiyear Breakout is a bullish signal for stocks. There are some prediction levels. These Levels act as Support and Resistance according to position of price. You have to trade according to level breakout or breakdown. Always maintain your risk management. Book your profit according to your “STOMACH”. Disclaimer: This is not investment advice. I am not a SEBI Registered Analyst. Anything posted here is my own analysis and views. This is created for educational purposes only. Always consult your Financial Advisor before taking any decision or trade. Happy trading. About GLAND : Gland Pharma Ltd. manufactures pharmaceutical ingredients and injectable formulations. It offers injectables including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, and ophthalmic solutions. The company was founded by P. V. N. Raju in 1978 and is headquartered in Sangareddy, India.
NSE:GLANDLong
by suraranjanganguli
Gland Pharma freezes at 20% upper circuitGland Pharma freezes at 20% upper circuit on strong June quarter show The firm's gross profit margin was up 700 bp year-on-year (YoY) to 63 per cent for Q1 due to lower raw material costs. On a sequential basis, gross profit margin improved by 900 bp from 54 per cent Shares of Gland Pharma were locked in the 20 per cent upper circuit at Rs 1,612.60 on the BSE in Tuesday’s intra-day trade after the company reported improved financial performance for the June quarter (Q1). The firm's gross profit margin was up 700 bp year-on-year (YoY) to 63 per cent for Q1 due to lower raw material costs. On a sequential basis, gross profit margin improved by 900 bp from 54 per cent.
NSE:GLAND
by chetnaparmar833
gland pharma - looks goodBased on the chart analysis, it appears that the stock is reaching a potential bottom point. This is indicated by a bullish divergence pattern at the all-time low, which typically suggests a possible reversal of the downward trend. Additionally, the stock has recently broken through a short-term resistance trendline, indicating a possible upward momentum. Disclaimer: However, it's important to note that these are short-term trading strategies and should be used with caution. It's always a good idea to consider the overall market conditions and the company's fundamental analysis before making any investment decisions. This is only for educational purpose.
NSE:GLAND
by hardeepssethi